Tcr2 Therapeutics (NASDAQ:TCRR) Stock Rating Upgraded by Zacks Investment Research

Tcr2 Therapeutics (NASDAQ:TCRR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The firm presently has a $17.00 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 8.77% from the stock’s previous close.

According to Zacks, “TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts. “

A number of other analysts also recently weighed in on TCRR. Roth Capital assumed coverage on shares of Tcr2 Therapeutics in a report on Friday, May 31st. They issued a “neutral” rating and a $16.00 price target for the company. ValuEngine raised shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $26.00.



Tcr2 Therapeutics stock traded up $0.46 during mid-day trading on Thursday, reaching $15.63. The company had a trading volume of 347 shares, compared to its average volume of 97,255. Tcr2 Therapeutics has a 52 week low of $10.04 and a 52 week high of $25.47. The stock’s 50 day simple moving average is $14.13. The stock has a market cap of $385.47 million and a price-to-earnings ratio of -0.16.

Tcr2 Therapeutics (NASDAQ:TCRR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. On average, equities analysts forecast that Tcr2 Therapeutics will post -5.66 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Parametric Portfolio Associates LLC lifted its holdings in shares of Tcr2 Therapeutics by 23.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock worth $501,000 after acquiring an additional 6,672 shares during the period. EcoR1 Capital LLC bought a new position in shares of Tcr2 Therapeutics during the 2nd quarter worth about $231,000. Laurion Capital Management LP bought a new position in shares of Tcr2 Therapeutics during the 1st quarter worth about $417,000. Charles Schwab Investment Management Inc. bought a new position in shares of Tcr2 Therapeutics during the 2nd quarter worth about $349,000. Finally, Dean Capital Investments Management LLC bought a new position in shares of Tcr2 Therapeutics during the 1st quarter worth about $694,000. 33.26% of the stock is owned by hedge funds and other institutional investors.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Article: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.